Create your Personal Health Record and unlock support built around you
- Treatments and trials you qualify for
- Education for your stage of care
- Financial support for your medications
- Solutions to your side effects
Beyond IMiDs: Cemsidomide — A Next-Generation Cereblon Degrader Shows Promise in Myeloma | EHA 2026
HealthTreeDescription
At EHA 2026, Dr. Sagar Lonial presented updated results from a first-in-human Phase 1 study of cemsidomide (CFT7455), a novel oral cereblon-based IKZF1/IKZF3 degrader designed to overcome resistance seen with older immunomodulatory drugs (IMiDs). The study explored cemsidomide plus dexamethasone in heavily pretreated relapsed/refractory multiple myeloma patients, including many previously exposed to CAR-T and bispecific antibodies.
If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu
For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!
Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.